CoChat

Defining the predictors of the placebo response in irritable bowel syndrome

Pitz, Marshall, Cheang, Mary, Bernstein, Charles N. · 2005 · Clinical Gastroenterology and Hepatology

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Background and aims We sought to determine the components of irritable bowel syndrome (IBS) clinical trials that correlate with higher levels of placebo response. Methods We performed a systematic review of placebo-controlled trials in patients with IBS to assess which variables correlate with a higher placebo response. Placebo responses for global symptom improvement and for decreased abdominal pain were assessed. Univariate and multiple linear regression analyses were conducted. Results Higher rates of global improvement correlated with frequency of administration of study intervention ( r = .31, P = .03), duration of the study ( r = .28, P = .04), and overall treatment effect of the active agent being studied ( r = .33, P = .02). Higher rates of decreased abdominal pain correlated with the frequency of intervention ( r = .39, P = .02) and overall treatment effect ( r = .40, P = .01), whereas lower placebo response rates correlated with year of the study ( r = -.36, P = .03), median age ( r = -.38, P = .04), and duration of study run-in period ( r = -.33, P = .04). On multivariate analysis, global improvement in the placebo group was associated significantly with intervention frequency ( P = .0079), overall treatment response ( P = .0031), and parallel study design ( P = .0044). Decreased abdominal pain was associated significantly with frequency of intervention ( P = .0061) and overall treatment response ( P = .0128). Conclusions In IBS studies, higher placebo response rat…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1542-3565(04)00626-3

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 102 · Cited by 111

Research works printed but not linked: 9

  1. Shetty, 1999, The placebo response in Parkinson’s disease, Clin Neuropharmacol, 22, 207
  2. Baldi, 1991, Clinical and functional evaluation of the efficacy of otilonium bromide, Ital J Gastroenterol, 23, 60
  3. Nayak, 1997, Metronidazole relieves symptoms in irritable bowel syndrome, Indian J Gastroenterol, 16, 137
  4. Baldi, 1992, Octylonium bromide in the treatment of the irritable bowel syndrome, Hepatogastroenterology, 39, 392
  5. Halpern, 1996, Treatment of irritable bowel syndrome with Lacteol Fort, Am J Gastroenterol, 91, 1579
  6. Misra, 1989, Long-term treatment of irritable bowel syndrome, QJM, 73, 931
  7. Tasman-Jones, 1973, Mebeverine in patients with the irritable colon syndrome, N Z Med J, 77, 232
  8. Yadav, 1989, Irritable bowel syndrome, Indian J Med Res, 90, 496
  9. Pimentel, 2003, Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome, Am J Gastroenterol, 98, 412

Metadata

Authors
Pitz, M., Cheang, M., & Bernstein, C. N.
Affiliations
University of Manitoba (CA)
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2005-03
Volume
3
Issue
3
Pages
237-247
ISSN
1542-3565 (ISSN-L)
OpenAlex
W2168787978
Cited by
111
References
102
Citations by year
2025: 3 · 2024: 2 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 2 · 2017: 5 · 2016: 3 · 2015: 7 · 2014: 11 · 2013: 4 · 2012: 4
FWCI
0.87
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • Clinical Gastroenterology and Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
irritable bowel syndrome, placebo response, predictors of placebo response, abdominal pain, intervention frequency, treatment effects, trial design, dosing frequency
MeSH terms
Clinical Trials as Topic, Drug Administration Schedule, Gastrointestinal Agents, Humans, Placebo Effect, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defining the predictors of the placebo response in irritable bowel syndrome. https://app.cochat.ai/papers/10.1016/s1542-3565(04)00626-3
The paper
Pitz, M., Cheang, M., & Bernstein, C. N. (2005). Defining the predictors of the placebo response in irritable bowel syndrome. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/s1542-3565(04)00626-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.